Trial Profile
Evaluation of Long-term Buprenorphine Plasma Exposure in Subjects Who Received at Least 2 Subcutaneous (SC) Injections of Extended-release Buprenorphine (SUBLOCADE) in Phase III Studies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Indivior
- 24 Jul 2019 Status changed from recruiting to completed.
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.